Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ABSK-011 |
| Synonyms | |
| Therapy Description |
ABSK-011 selectively inhibits FGFR4, resulting in decreased downstream signaling and potentially leading to inhibition of tumor growth (Cancer Res (2018) 78 (13_Supplement): LB-272). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ABSK-011 | ABSK 011|ABSK011|irpagratinib | FGFR4 Inhibitor 10 | ABSK-011 selectively inhibits FGFR4, resulting in decreased downstream signaling and potentially leading to inhibition of tumor growth (Cancer Res (2018) 78 (13_Supplement): LB-272). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04906434 | Phase I | ABSK-011 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor | Recruiting | USA | 2 |